RecruitingNot ApplicableNCT07341893
Sacubitril-valsartan in Patients With Heart Failure.
Clinical Study Evaluating Efficacy and Safety Sacubitril-valsartan in Patients With Heart Failure.
Sponsor
Damanhour University
Enrollment
60 participants
Start Date
Aug 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of this study is to evaluate the safety and efficacy of Sacubitril -Valsartan in patients with heart failure.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria3
- Age ≥ 18 years old for both genders.
- LV ejection fraction (LVEF) ≤40%.
- Heart failure patients with NYHA grade II-IV.
Exclusion Criteria7
- CKD with GFR \< 20 ml/min/1.73
- Serum potassium \< 5.5 mmol / L.
- Pregnant or lactating women
- Active infection.
- Congenital heart disease.
- Autoimmune disorders or connective tissue disorders.
- Severe hepatic dysfunction.
Interventions
DRUGSacubitril-valsartan
patients (n=30) will be given Sacubitril-valsartan 50 mg twice daily.
DRUGstandard treatment of heart failure
Control group (n=30) on standard treatment of heart failure.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07341893
Related Trials
Mind Your Heart-II
NCT054311921 location
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288652 locations
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
NCT0700216420 locations
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
NCT071917301 location
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370641 locations